1Parkin DM, Bray F, Ferlay J. Global cancer statistics, 2002 [ J ]. CA Cancer J Clin,2005,55 : 74 - 108.
2Long XD, Ma Y, Wei YP, et al. The polymorphisms of GSTM 1, GSTF1, HYL 1 * 2, and XRCC 1, and aflatoxin B1-related hepato cellular carcinoma in Guangxi population, China [ J ]. Hepatol Res,2006,36( 1 ) :48 -55.
6Hunag S, Shen Q, Mao WG, et al. JWA, a novel signaling molecule, involved in the induction of diefferentation of human myeloid leukemia cells[ J]. Biochem Biophys Res Commu ,2006, 341 : 440-450.
7Zhu T, Chen R, Zhou JW, et al. Regulation of a novel cell differentiation assoeiated gfene, JWA, during oxidative damage in K562 and MCF-7 cells[ J]. J Boimfed Sci,2005,12 : 219 - 227.
4Ferguson R.I, De MorNs SM, Benhamou S, et al. A new genetic defect in human CYP2C19:mutation of the initiation codon is responsible for poor metabolism of S2 mephenytoin[ J], J Pharmcol Exp Ther,1998,284( 1 ) :356 -361.
5Shirai N, Furuta T, Moriyama Y, et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazoleon intragastrie pH[ J ].Aliment Pharmaeol Ther ,2001,15 (12) : 1929 - 1937.
6Sakai T, Aoyama N, Kita T, et al. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects [J]. Pharm Res,2001,18(6) :721 -727.
7Hyttel J, Bogeso KP, Perregaard J, et al. The pharmacological effect of citalopram resides in the (S)-( + )-enantiomer[ J]. J Neural Transm Gen Sect, 1992,88 : 157 - 160.
8Kaneko A, Bergqvist Y, Taleo G, et al. Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations[ J ]. Pharmaeo genetics, 1999,9 ( 3 ) :317 - 326.
9De MorNs SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans [ J ]. J Biol Chem, 1994,269 ( 22 ) : 15419 - 15422.
10Garner E, Raj K. Protective mechanisms of p53-p21-pRb proteins against DNA damage-induced cell death [ J]. Cell Cycle, 2008,7 (3) :277 -282.
